Utpal Chandra De

Utpal Chandra De

Auto-generated profile, based on publicly available information

Utpal Chandra De

Department of Chemistry, Tripura University, Suryamaninagar, 799022, Tripura, India

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2023 in RSC Advances
Verified
Journal Article
Open access
PDF file
SCSourav Chakraborty
Sourav Chakraborty
BPBhaswati Paul
Bhaswati Paul
UDUtpal Chandra De
Utpal Chandra De
RNRamalingam Natarajan
Ramalingam Natarajan
SMSwapan Majumdar
Swapan Majumdar
Here, we report a simple, efficient, and green protocol for the one-pot synthesis of pyrano[2,3- c ]pyrazole derivatives via a sequential three-component strategy using aromatic aldehydes, malononitrile and pyrazolinone in a water–SDS–IL system.

29 November 2019 in Microbial Pathogenesis
Verified
Journal Article
Closed access
CGChinmoy Ghosh
Chinmoy Ghosh
JBJoyanta Bhowmik
Joyanta Bhowmik
RGRanjit Ghosh
Ranjit Ghosh
MDManash C. Das
Manash C. Das
PSPadmani Sandhu
Padmani Sandhu
SBSurajit Bhattacharjee
Surajit Bhattacharjee

12 January 2021 in Molecular Diversity
Verified
Journal Article
Closed access
PDF file
SBSukhen Bhowmik
Sukhen Bhowmik
PAPragya Anand
Pragya Anand
RDRiyanki Das
Riyanki Das
TSTirtharaj Sen
Tirtharaj Sen
YAYusuf Akhter
Yusuf Akhter
UDUtpal C. De
Utpal C. De

18 August 2022 in Journal of the American Nutrition Association
Verified
Journal Article
Closed access
MPMunia Parvin
Munia Parvin
ARAshikur Rahaman
Ashikur Rahaman
ASArnab Sarkar
Arnab Sarkar
SDSudhan Debnath
Sudhan Debnath
UDUtpal Chandra De
Utpal Chandra De
Shamee BhattacharjeeShamee Bhattacharjee
Shamee Bhattacharjee
Oral squamous cell carcinoma (OSCC) is the predominant type of oral cancer. Its incidence is high in certain geographic regions, and it is correlated with chewing tobacco. Epidermal growth factor r...

7 July 2017 in Chemistry & Biodiversity
Verified
Journal Article
Closed access
PDF file
RGRanjit Ghosh
Ranjit Ghosh
MDManash C. Das
Manash C. Das
ASArpita Sarkar
Arpita Sarkar
ADAntu Das
Antu Das
PSPadmani Sandhu
Padmani Sandhu
UDUtpal Ch. De
Utpal Ch. De

1 October 2025 in Anti-Cancer Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
BMBijayashree Mishra
Bijayashree Mishra
PAPratap Chandra Acharya
Pratap Chandra Acharya
UDUtpal Chandra De
Utpal Chandra De
Anthraquinones are well known for their wide spectrum of pharmacological properties. Anthraquinone antibiotics, such as doxorubicin, daunorubicin, epirubicin, and mitoxantrone, have long been used in the clinical management of various tumors. However, their use is limited due to their toxicity effects, especially cardiomyopathy, despite their pronounced therapeutic effects. In recent years, medicinal chemists have explored the possibility of modifying the anthraquinone ring appended with structurally diverse functionality in order to develop better chemotherapeutic agents with fewer adverse effects. The fused polycyclic structure of anthraquinone offers rigidity, planarity, and aromaticity, which helps in double helix DNA intercalation, disruption of G4 DNA, and inhibition of topoisomerase-II enzyme of cancer cells, making them suitable pharmacophore for anticancer drug discovery. Incorporation of suitable functional groups such as amino, hydroxyl, and their derivatives into anthraquinone rings can improve their interactions with biological targets involved in cancer progression. These subtle structural changes produce newer anthraquinone derivatives with improved anticancer properties, increased potency, selectivity, and reduced toxicity, and can overcome multi-drug resistance. On the other hand, the molecular hybrids of the anthraquinone derivatives have been reported to act on multiple targets in cancer cells, as seen in the case of clinical candidates like alectinib, midostaurin, tucatinib, belinostat, and dacinostat. Molecular hybrid has given a new direction for anticancer drug development, which can produce bifunctional drug candidates with reduced toxicity. This review summarizes different structural modifications that have been made to the anthraquinone ring in the last decade with the aim of bringing out potent yet toxicity-free anticancer agents.